BiondVax Pharmaceuticals Universal Flu Vaccine
Prepare to have your mind blown. A tiny little company called BiondVax Pharmaceuticals claims to have a flu immunization shot which will protect against future flu strains that don’t even exist yet! Sounds crazy but if this company really has produced a next generation flu shot capable of being a universal flu vaccine, the stock in this company is going to explode higher.
Flu vaccines are a $4.3 billion market. Current flu vaccines are limited to just 3 or 4 existing strains. Furthermore, seasonal flu vaccine effectiveness is only about 40% on average and as low as 9% in the elderly who are the most at risk group. Conversely, as a universal flu vaccine candidate, M-001 from BiondVax Pharmaceuticals is designed to provide improved and broad protection against all current and future seasonal and pandemic flu strains. The company published a paper in the journal Vaccine on their universal flu vaccine candidate M-001 where they showed the results of an immunization with M-001 prior to trivalent influenza vaccine in 2011-2012 and how it enhanced a protective immune responses against the 2014-2015 epidemic strain.
The Vaccine article reports that blood plasma samples from people who received M-001 in 2011 (as part of BiondVax’s BVX-005 clinical trial in the elderly) showed significantly increased protective antibodies against the new epidemic 2014-2015 flu strain, a strain which did not exist when M-001 was administered to the BVX-005 participants!
BiondVax Pharmaceuticals Stock Chart
GO HERE TO CHART LARGE PLAYERS AND THE TWIGGS MONEY FLOW LIKE THE CHART ABOVE… AWESOME TOOL
Lance Jepsen
Latest posts by Lance Jepsen (see all)
- Sign Housing Market Is Teetering On the Edge of Collapse - June 25, 2017
- United States Economy Teetering On Collapse - June 25, 2017
- Cheniere Energy Adds South Korea to Growing List of Customers - June 25, 2017
